PCL2 regulates p53 stability and functions as a tumor suppressor in breast cancer

被引:1
|
作者
Yiran Liang [1 ,2 ]
Yang Yang [1 ]
Renbo Guo [3 ]
Shuang Gao [1 ]
Xinghong Guo [1 ]
Danyang Li [1 ]
Meng Wang [1 ]
Haruhiko Koseki [4 ]
Xiangzhi Li [1 ]
机构
[1] Department of Cell Biology,Shandong University School of Basic Medical Sciences
[2] Department of Breast Surgery,Qilu Hospital of Shandong University
[3] Department of Urology,Shandong Cancer Hospital Affiliated to Shandong University
[4] Laboratory for Developmental Genetics,RIKEN Center for Integrative Medical Sciences
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
Polycomb repressive complexes; PCL2; p53; MDM2; Breast cancer;
D O I
暂无
中图分类号
R737.9 [乳腺肿瘤];
学科分类号
摘要
Polycomblike2(PCL2) is a well-known component of polycomb repressive complex 2(PRC2) and plays important roles in H3 K27 methylation and homeotic gene silencing.However,the involvement of PCL2 in breast cancer development remains unclear.Here,we established PCL2 as a tumor suppressor gene in breast cancer.Expression level of PCL2 was significantly downregulated in breast cancer tissue samples observed at different TNM stages.Ectopic expression of PCL2 could significantly inhibit cell proliferation and promoted apoptosis.PCL2 also remarkably elevated levels of p53 and its targets by increasing p53 stability.Mechanistically,PCL2 protected p53 proteins from MDM2-mediated ubiquitination and degradation by sequestering MDM2 into the nucleolus.Overexpression of PCL2 also suppressed migration and invasion by inhibiting epithelial-mesenchymal transition.PCL2 expression was correlated with Ecadherin expression and was inversely correlated with vimentin expression.Furthermore,PCL2 knockdown could attenuate anti-tumor effect of MLN4924.Taken together,our findings indicated that PCL2 played a tumor suppressor role in development and progression of breast cancer and may be a prognostic and predictive marker for breast cancer.
引用
收藏
页码:629 / 639
页数:11
相关论文
共 50 条
  • [31] Advancements in targeting tumor suppressor genes (p53 and BRCA 1/2) in breast cancer therapy
    Nainwal, Nidhi
    Murti, Yogesh
    Yadav, Savita
    Rawat, Pramod
    Dhiman, Sonia
    Kumar, Bhupinder
    MOLECULAR DIVERSITY, 2024,
  • [32] TUMOR-SUPPRESSOR P53 MUTATIONS AND BREAST-CANCER - A CRITICAL ANALYSIS
    OZBUN, MA
    BUTEL, JS
    ADVANCES IN CANCER RESEARCH, VOL 66, 1995, 66 : 71 - 141
  • [33] THE P53 TUMOR SUPPRESSOR GENE
    LEVINE, AJ
    MOMAND, J
    FINLAY, CA
    NATURE, 1991, 351 (6326) : 453 - 456
  • [34] Tumor suppressor p53 and metabolism
    Liu, Juan
    Zhang, Cen
    Hu, Wenwei
    Feng, Zhaohui
    JOURNAL OF MOLECULAR CELL BIOLOGY, 2019, 11 (04) : 284 - 292
  • [35] THE TUMOR-SUPPRESSOR P53
    DONEHOWER, LA
    BRADLEY, A
    BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1155 (02) : 181 - 205
  • [36] p53: not just a tumor suppressor
    Oren, Moshe
    JOURNAL OF MOLECULAR CELL BIOLOGY, 2019, 11 (07) : 539 - 543
  • [37] P53 TUMOR SUPPRESSOR GENE
    SOUSSI, T
    BULLETIN DU CANCER, 1993, 80 (02) : 96 - 101
  • [38] Cellular UV damage responses - Functions of tumor suppressor p53
    Latonen, L
    Laiho, M
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2005, 1755 (02): : 71 - 89
  • [39] Grail as a molecular determinant for the functions of the tumor suppressor p53 in tumorigenesis
    Chen, Y-C
    Chan, Jy-H
    Chiu, Y-L
    Liu, S-T
    Lozano, G.
    Wang, S-L
    Ho, C-L
    Huang, S-M
    CELL DEATH AND DIFFERENTIATION, 2013, 20 (05): : 732 - 743
  • [40] Grail as a molecular determinant for the functions of the tumor suppressor p53 in tumorigenesis
    Y-C Chen
    J Y-H Chan
    Y-L Chiu
    S-T Liu
    G Lozano
    S-L Wang
    C-L Ho
    S-M Huang
    Cell Death & Differentiation, 2013, 20 : 732 - 743